William Blair initiated coverage of Ocular Therapeutix (OCUL) with an Outperform rating and fair value of $18 per share. Ocular is a commercial biotech company with its lead clinical asset Axpaxli, a long-acting axitinib hydrogel implant, in Phase III studies for neovascular age-related macular degeneration, with potential expansion into other retinal vascular diseases, the analyst tells investors in a research note. The firm believes the emerging class of long-acting tyrosine kinase inhibitors have the potential to meaningfully change the treatment paradigm for nAMD, and that Axpaxli has the potential to show best-in-class efficacy and durability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix initiated with an Outperform at William Blair
- Buy Recommendation for Ocular Therapeutix: Axpaxli’s Potential to Revolutionize nAMD Treatment
- Ocular Therapeutix added to Analyst Current Favorites list at Raymond James
- Ocular Therapeutix initiated with an Outperform at RBC Capital
- Beam, Unity, Checkpoint, Inuvo, Ocular: Trending by Analysts